Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Yashar D, Spektor TM, Martinez D, Ghermezi M, Swift RA, Eades B, Schwartz G, Eshaghian S, Lim S, Vescio R, Berenson JR. Yashar D, et al. Among authors: lim s. Leuk Lymphoma. 2022 Apr;63(4):975-983. doi: 10.1080/10428194.2021.2005044. Epub 2021 Nov 24. Leuk Lymphoma. 2022. PMID: 34818965 Clinical Trial.
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Daniely D, Forouzan E, Spektor TM, Cohen A, Bitran JD, Chen G, Moezi MM, Bessudo A, Hrom J, Eshaghian S, Swift RA, Eades BM, Kim C, Lim S, Berenson JR. Daniely D, et al. Among authors: lim s. Exp Hematol. 2022 Jul;111:79-86. doi: 10.1016/j.exphem.2022.04.003. Epub 2022 Apr 10. Exp Hematol. 2022. PMID: 35417741 Free article. Clinical Trial.
Temozolomide: a novel treatment for pituitary carcinoma.
Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Lim S, et al. Lancet Oncol. 2006 Jun;7(6):518-20. doi: 10.1016/S1470-2045(06)70728-8. Lancet Oncol. 2006. PMID: 16750503 No abstract available.
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Lim S, Vescio R. Berenson JR, et al. Among authors: lim s. Clin Cancer Res. 2020 May 15;26(10):2346-2353. doi: 10.1158/1078-0432.CCR-19-1899. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937615 Clinical Trial.
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Berenson JR, Limon A, Rice S, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Brobeck M, Swift R, Eades BM, Bujarski S, Sebhat Y, Ray R, Kim S, Del Dosso A, Vescio R. Berenson JR, et al. Among authors: lim s. Target Oncol. 2024 Apr 20. doi: 10.1007/s11523-024-01049-w. Online ahead of print. Target Oncol. 2024. PMID: 38643346
15,499 results
You have reached the last available page of results. Please see the User Guide for more information.